New and improved retinal organoids for better drug testing
Original story from Universitätsklinikum Bonn (Germany).
Breakthrough in retinal organoid research as researchers create vascular networks that enhance survival and function of retinal cells.
Until now, it has been difficult to maintain retinal ganglion cells deep inside organoids over extended periods. The supply of nutrients and oxygen in the densely packed tissues is limited, leading to cell death. The international team led by Volker Busskamp at the University Hospital Bonn, the University of Bonn and the Institute of Molecular and Clinical Ophthalmology Basel (all Germany) solved this problem by combining human stem cell-derived retinal organoids with endothelial cells, which integrate into the organoids and create lumen-like networks that transport nutrients and oxygen – a crucial requirement for preserving sensitive retinal ganglion cells. In vivo, axons of retinal ganglion cells are forming the optic nerve and relay visual information from the retina to higher brain areas.
The scientists tested several methods for integrating the vascular cells and found that pre-cultured endothelial cells integrate best into already formed organoid spheres. This approach preserves developmental processes while significantly increasing the number of surviving ganglion cells. Analyses show that cell types in the vascularized retinal organoids differentiate normally, while optic nerve cells survive longer and achieve higher functional maturity.
Award winner discusses potential of retinal organoids
How retinal organoids offer powerful disease-modeling capabilities and the promise of stem cell-derived retinal cell replacement therapies for treating sight loss resulting from retinal degeneration.
To examine ganglion cell activity, the researchers used microelectrodes and microfluidic devices that allow the axons of ganglion cells to grow stably. In these vascularized retinal organoids, the retinal ganglion cells are more active: they send electrical signals more frequently, more synchronously and with higher intensity than cells in non-vascularized organoids. Using optogenetic techniques, the cells could be precisely stimulated with light, resulting in markedly stronger and more reliable responses. After several weeks of maturation, the vascularized organoids formed functional light-signal pathways: photoreceptors responded to light stimuli, and the signals were correctly transmitted to the ganglion cells, including the typical ON, OFF and ON-OFF response patterns.
“Incorporation of vascular cells dramatically improves ganglion cell survival and function, enabling the first comprehensive in vitro demonstration of vertical signal transmission from photoreceptors to ganglion cells. This advance establishes retinal organoids as a functional in vitro platform for studying human retinal development and disease,” explained Volker Busskamp, corresponding author of the study and head of the Degenerative Retinal Diseases research group at the University Hospital Bonn. He is also a member of the Transdisciplinary Research Area (TRA) ‘Life and Health’ of the University of Bonn.
Furthermore, the vascularized organoids demonstrated the ability to respond to hypoxia. Under low-oxygen conditions, the artificial vessels formed new networks, similar to changes seen in certain retinal diseases. This opens up possibilities for modeling conditions such as retinopathy of prematurity and for testing new therapeutic approaches.
The method is simple to apply and can be adapted to other organoid models. Vascularized retinal organoids now provide more sophisticated human retinal models that contain functional retinal ganglion cells and allow the development of light-signal pathways in the lab. These advances offer new perspectives for studying retinal diseases, testing drugs and developing future therapies.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.